Myriad Genetics Inc (MYGN) stock
MYGNNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 8/3070% below fair value
$5.53−0.01 (-0.18%)
Close on Nov 18, 2026Market cap $528.94MP/E –Yield –
Myriad Genetics market cap
Market capitalization is the share price multiplied by the number of shares outstanding.
Myriad Genetics's market cap was $546.83M on Nov 11, 2026, against $710.35M a year earlier. Over the last 5 years it ranged from $269.98M to $2.58B, with a median of $1.53B.
Market Cap at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $546.83M | -4.5% |
| 2025 | Dec 31, 2025 | $572.57M | -54.1% |
| 2024 | Dec 31, 2024 | $1.25B | -20.6% |
| 2023 | Dec 29, 2023 | $1.57B | +33.9% |
| 2022 | Dec 30, 2022 | $1.17B | -43.1% |
| 2021 | Dec 31, 2021 | $2.06B | +39.6% |
| 2020 | Dec 31, 2020 | $1.48B | -27.1% |
| 2019 | Dec 31, 2019 | $2.03B | -6.7% |
| 2018 | Dec 31, 2018 | $2.17B | -8.6% |
| 2017 | Dec 29, 2017 | $2.38B | +108.4% |
| 2016 | Dec 30, 2016 | $1.14B | -61.9% |
| 2015 | Dec 31, 2015 | $3.00B | +20.5% |
| 2014 | Dec 31, 2014 | $2.49B | +54.3% |
| 2013 | Dec 31, 2013 | $1.61B | -27.3% |
| 2012 | Dec 31, 2012 | $2.22B | +25.2% |
| 2011 | Dec 30, 2011 | $1.77B | -16.0% |
| 2010 | Dec 31, 2010 | $2.11B | -18.0% |
| 2009 | Dec 31, 2009 | $2.57B | – |
See a number that looks wrong?